The FDA approved crizanlizumab-tmca (Adakveo, Novartis), a treatment to reduce the frequency of vaso-occlusive crisis (VOC), a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells.
Crizanlizumab-tmca is indicated for patients aged 16 years and older.